{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:00:44Z","timestamp":1784779244931,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00210-026-05322-9","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:59:53Z","timestamp":1776916793000},"page":"16531-16539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety assessment of Neulasta\u00ae (pegfilgrastim) in patients with solid tumors: a real-world adverse event analysis from the FAERS database"],"prefix":"10.1007","volume":"399","author":[{"given":"Keyun","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"5322_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac074","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyac074","journal-title":"Oncologist"},{"key":"5322_CR2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0249-y","author":"A Brekkan","year":"2018","unstructured":"Brekkan A, Lopez-Lazaro L, Yngman G, Plan EL, Acharya C, Hooker AC, Kankanwadi S, Karlsson MO (2018) A population pharmacokinetic-pharmacodynamic model of pegfilgrastim. AAPS J. https:\/\/doi.org\/10.1208\/s12248-018-0249-y","journal-title":"AAPS J"},{"key":"5322_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.10.008","author":"P Dwivedi","year":"2017","unstructured":"Dwivedi P, Greis KD (2017) Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol. https:\/\/doi.org\/10.1016\/j.exphem.2016.10.008","journal-title":"Exp Hematol"},{"key":"5322_CR4","unstructured":"Food and Drug Administration (n.d.) FDA Adverse Event Reporting System (FAERS) public dashboard. Retrieved from https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 2\u00a0May 2025"},{"key":"5322_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23726-4","author":"M Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, Li J, Li F (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-23726-4","journal-title":"Sci Rep"},{"key":"5322_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1148\/radiol.221712","volume":"2022","author":"G Krinsky","year":"2022","unstructured":"Krinsky G (2022) Pegfilgrastim-induced aortitis: cardiovascular diagnosis in the oncologic setting. Radiology 2022:741\u2013742. https:\/\/doi.org\/10.1148\/radiol.221712","journal-title":"Radiology"},{"key":"5322_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.08.006","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"5322_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07103-5","author":"H Link","year":"2022","unstructured":"Link H (2022) Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF). Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-022-07103-5","journal-title":"Support Care Cancer"},{"key":"5322_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08258-w","author":"R Mahtani","year":"2021","unstructured":"Mahtani R, Crawford J, Flannery SM, Lawrence T, Schenfeld J, Gawade PL (2021) Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-021-08258-w","journal-title":"BMC Cancer"},{"key":"5322_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2023.12.004","author":"J Mazzola","year":"2024","unstructured":"Mazzola J, Hennon P, Peine K, Siedlecki SL (2024) Effect of loratadine for pegfilgrastim-induced bone pain. Pain Manag Nurs. https:\/\/doi.org\/10.1016\/j.pmn.2023.12.004","journal-title":"Pain Manag Nurs"},{"key":"5322_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06230-9","author":"M Metz","year":"2021","unstructured":"Metz M, Semsek D, Rogmans G, Hutzschenreuter U, Fietz T, Harde J, Zacharias S, Hielscher C, Lorenz A, Zahn M-O, Guth D, Liebers S, Berghorn M, Grebhardt S, Matillon CD, Egerer G, Potthoff K (2021) Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-021-06230-9","journal-title":"Support Care Cancer"},{"key":"5322_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.04.017","author":"DM Piedmonte","year":"2008","unstructured":"Piedmonte DM, Treuheit MJ (2008) Formulation of Neulasta (pegfilgrastim). Adv Drug Deliv Rev. https:\/\/doi.org\/10.1016\/j.addr.2007.04.017","journal-title":"Adv Drug Deliv Rev"},{"key":"5322_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215585188","author":"PA Pawloski","year":"2016","unstructured":"Pawloski PA, Larsen M, Thoresen A, Giordana MD (2016) Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients. J Oncol Pharm Pract. https:\/\/doi.org\/10.1177\/1078155215585188","journal-title":"J Oncol Pharm Pract"},{"key":"5322_CR14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220011","author":"DF Quail","year":"2022","unstructured":"Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, Goodridge HS, Granot Z, Hidalgo A, Huttenlocher A, Kaplan MJ, Malanchi I, Merghoub T, Meylan E, Mittal V, Pittet MJ, Rubio-Ponce A, Udalova IA, van den Berg TK, Wagner DD, Wang P, Zychlinsky A, Visser K, Egeblad M, Kubes P (2022) Neutrophil phenotypes and functions in cancer: a consensus statement. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20220011","journal-title":"J Exp Med"},{"key":"5322_CR15","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"5322_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-024-00778-y","author":"JP Strydom","year":"2024","unstructured":"Strydom JP, Brand L, Viljoen FP, Wolmarans DW (2024) Differential impact of pegfilgrastim, a recombinant human granulocyte colony stimulating factor, on the neutrophil count of male and female deer mice (Peromyscus maniculatus bairdii). BMC Pharmacol Toxicol. https:\/\/doi.org\/10.1186\/s40360-024-00778-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"5322_CR17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5322_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026377","author":"A Theyab","year":"2022","unstructured":"Theyab A, Alsharif KF, Alzahrani KJ, Oyouni AAA, Hawsawi YM, Algahtani M, Alghamdi S, Alshammary AF (2022) New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.1026377","journal-title":"Front Oncol"},{"key":"5322_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03649-0","author":"Y Uemura","year":"2023","unstructured":"Uemura Y, Oshima K, Fuseya A, Hosokai A, Ohashi A, Kanno M, Arai A (2023) Aortitis after administration of pegfilgrastim to a healthy donor for peripheral blood stem cell collection. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-023-03649-0","journal-title":"Int J Hematol"},{"key":"5322_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1391356","volume":"15","author":"M-T Wen","year":"2024","unstructured":"Wen M-T, Li J-C, Lu B-W, Shao H-R, Ling P-X, Liu F, Li G, Luo D (2024) Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS). Front Pharmacol 1391356. https:\/\/doi.org\/10.3389\/fphar.2024.1391356","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05322-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05322-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05322-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:01:33Z","timestamp":1784775693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05322-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5322"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05322-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}